NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases

International Journal of Cancer

Volumn 137, Issue 5, 2015, Pages 1085-1094

  Sadegh, Leila ^a   Chen, Peter W ^a   Brown, Joseph R ^a   Han, Zhiqiang ^a   Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

eye; IL 10; metastases; NKG2D; ocular tumors; uveal melanoma

Indexed keywords

CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; LYMPHOCYTE ANTIBODY; ANTIBODY; CD1D ANTIGEN, MOUSE; IL10 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE EXACERBATION; FEMALE; KUPFFER CELL; LIVER METASTASIS; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; UPREGULATION; UVEA MELANOMA; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; GENETICS; IMMUNOLOGY; LIVER TUMOR; LYMPHOCYTE ACTIVATION; MELANOMA; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL LINE; UVEA TUMOR;

ANIMALS; ANTIBODIES; ANTIGENS, CD1D; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; INTERFERON-GAMMA; INTERLEUKIN-10; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; NEOPLASM TRANSPLANTATION; RECEPTORS, INTERLEUKIN-10; UVEAL NEOPLASMS;

EID: 84931561333     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29480     Document Type: Article

References (48)

1. Bakalian S, Marshall JC, Logan P, et al., Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 2008; 14: 951-6.
2. Feldman ED, Pingpank JF, Alexander HR, Jr,. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004; 11: 290-7.
3. Crispe IN,. The liver as a lymphoid organ. Annu Rev Immunol 2009; 27: 147-63.
4. Thomson AW, Knolle PA,. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010; 10: 753-66.
5. O'Farrelly C, Crispe IN,. Prometheus through the looking glass: reflections on the hepatic immune system. Immunol Today 1999; 20: 394-8.
6. Niederkorn JY,. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res 2009; 28: 329-47.
7. Yang W, Li H, Mayhew E, et al., NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice. Investig Ophthalmol Vis Sci 2011; 52: 3094-102.
8. Terabe M, Berzofsky JA,. The role of NKT cells in tumor immunity. Adv Cancer Res 2008; 101: 277-348.
9. Gao B, Radaeva S, Park O,. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 2009; 86: 513-28.
10. Bendelac A, Savage PB, Teyton L,. The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336.
11. Morales JK, Kmieciak M, Graham L, et al., Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother 2009; 58: 941-53.
12. Ostrand-Rosenberg S, Sinha P,. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-506.
13. Alizadeh H, Howard K, Mellon J, et al., Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. Investig Ophthalmol Vis Sci 2003; 44: 3042-51.
14. Reinmuth N, Liu W, Ahmad SA, et al., Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 2003; 63: 2079-87.
15. Kuruppu D, Christophi C, Bertram JF, et al., Characterization of an animal model of hepatic metastasis. J Gastroenterol Hepatol 1996; 11: 26-32.
16. Van Rooijen N,. The liposome-mediated macrophage 'suicide' technique. J Immunol Methods 1989; 124: 1-6.
17. Traeger T, Mikulcak M, Eipel C, et al., Kupffer cell depletion reduces hepatic inflammation and apoptosis but decreases survival in abdominal sepsis. Eur J Gastroenterol Hepatol 2010; 22: 1039-49.
18. Jamieson T, Clarke M, Steele CW, et al., Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Investig 2012; 122: 3127-44.
19. Daley JM, Thomay AA, Connolly MD, et al., Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukocyte Biol 2008; 83: 64-70.
20. Knolle PA, Gerken G,. Local control of the immune response in the liver. Immunol Rev 2000; 174: 21-34.
21. Moore KW, de Waal Malefyt R, Coffman RL, et al., Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
22. Bauer S, Groh V, Wu J, et al., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
23. Raulet DH, Gasser S, Gowen BG, et al., Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413-41.
24. Zafirova B, Wensveen FM, Gulin M, et al., Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 2011; 68: 3519-29.
25. Diefenbach A, Jensen ER, Jamieson AM, et al., Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-71.
26. Raulet DH,. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781-90.
27. Raulet DH, Guerra N,. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9: 568-80.
28. Metelitsa LS, Weinberg KI, Emanuel PD, et al., Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003; 17: 1068-77.
29. Wu DY, Segal NH, Sidobre S, et al., Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 2003; 198: 173-81.
30. Song L, Asgharzadeh S, Salo J, et al., Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Investig 2009; 119: 1524-36.
31. Terabe M, Matsui S, Noben-Trauth N, et al., NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515-20.
32. Park JM, Terabe M, van den Broeke LT, et al., Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer 2005; 114: 80-7.
33. Terabe M, Swann J, Ambrosino E, et al., A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005; 202: 1627-33.
34. Bricard G, Cesson V, Devevre E, et al., Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 2009; 182: 5140-51.
35. Jewett A, Tseng HC,. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer 2011; 2: 443-57.
36. Apte RS, Niederkorn JY,. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol 1996; 156: 2667-73.
37. Apte RS, Sinha D, Mayhew E, et al., Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 1998; 160: 5693-6.
38. Couper KN, Blount DG, Riley EM,. IL-10: the master regulator of immunity to infection. J Immunol 2008; 180: 5771-7.
39. Hsu DH, Moore KW, Spits H,. Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. Int Immunol 1992; 4: 563-9.
40. Rook AH, Kehrl JH, Wakefield LM, et al., Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136: 3916-20.
41. Seino K, Taniguchi M,. Functionally distinct NKT cell subsets and subtypes. J Exp Med 2005; 202: 1623-6.
42. Zhang LJ, Wang XZ,. Interleukin-10 and chronic liver disease. World J Gastroenterol 2006; 12: 1681-5.
43. Couper KN, Blount DG, Riley EM,. IL-10: the master regulator of immunity to infection. J Immunol 2008; 180: 5771-7.
44. Mocellin S, Panelli MC, Wang E, et al., The dual role of IL-10. Trends Immunol 2003; 24: 36-43.
45. Zheng LM, Ojcius DM, Garaud F, et al., Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184: 579-84.
46. Subleski JJ, Hall VL, Back TC, et al., Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res 2006; 66: 11005-12.
47. Carnaud C, Lee D, Donnars O, et al., Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999; 163: 4647-50.
48. Smyth MJ, Wallace ME, Nutt SL, et al., Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 2005; 201: 1973-85.